The following information has been compiled from publicly available sources,
StratCom does not assume any responsibility for the accuracy or the authenticity
of the information and StratCom cannot be held liable for errors.
Bayer Biological Products, a division of Bayer Corporation has been selected to continue as the primary supplier to the blood system in Canada. Canadian Blood Services and Hema-Quebec, recently signed multi-year agreements with Bayer to supply commercial products and fractionation services including Kogenate FS, Gamimune N, 10%, BayHep B, Plasbumin 5%, and BayGam. As part of the agreements, Bayer will continue to invest in a Partnership Fund dedicated to supporting research and development in blood products and will provide annual contributions to Canadian Blood Services and Hema-Quebec for respective public education programs.
An $18.1-million Heart and Stroke Research Centre for cardiovascular research, operated by the University of Alberta in partnership with the Capital Health Region will in late 2003. Researchers will undertake translational, basic science and outcomes research as well as clinical trials. The goal is to advance the fundamental understanding of human cardiac and vascular diseases. Dr. Stephen Archer, a professor of medicine and physiology in the faculty of medicine and dentistry at the University of Alberta will be the director of the new centre.
![[Page Banner Image]](images/hcare.gif){kind=small}
![[HRule Image]](images/div.jpg){kind=small}
